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Abstract
Background: Candidate compounds being developed to treat chronic obstructive pulmonary disease are typically
assessed using either acute or chronic mouse smoking models; however, in both systems compounds have almost
always been administered prophylactically. Our aim was to determine whether the prophylactic effects of reference
anti-inflammatory compounds in acute mouse smoking models reflected their therapeutic effects in (more clinically
relevant) chronic systems.
Methods: To do this, we started by examining the type of inflammatory cell infiltrate which occurred after acute (3
days) or chronic (12 weeks) cigarette smoke exposure (CSE) using female, C57BL/6 mice (n = 7-10). To compare the
effects of anti-inflammatory compounds in these models, mice were exposed to either 3 days of CSE concomitant
with compound dosing or 14 weeks of CSE with dosing beginning after week 12. Budesonide (1 mg kg
-1; i.n., q.d.),
roflumilast (3 mg kg
-1; p.o., q.d.) and fluvastatin (2 mg kg
-1; p.o., b.i.d.) were dosed 1 h before (and 5 h after for
fluvastatin) CSE. These dose levels were selected because they have previously been shown to be efficacious in
mouse models of lung inflammation. Bronchoalveolar lavage fluid (BALF) leukocyte number was the primary
endpoint in both models as this is also a primary endpoint in early clinical studies.
Results: To start, we confirmed that the inflammatory phenotypes were different after acute (3 days) versus
chronic (12 weeks) CSE. The inflammation in the acute systems was predominantly neutrophilic, while in the more
chronic CSE systems BALF neutrophils (PMNs), macrophage and lymphocyte numbers were all increased (p < 0.05).
In the acute model, both roflumilast and fluvastatin reduced BALF PMNs (p < 0.01) after 3 days of CSE, while
budesonide had no effect on BALF PMNs. In the chronic model, therapeutically administered fluvastatin reduced
the numbers of PMNs and macrophages in the BALF (p ≤ 0.05), while budesonide had no effect on PMN or
macrophage numbers, but did reduce BALF lymphocytes (p < 0.01). Roflumilast’s inhibitory effects on inflammatory
cell infiltrate were not statistically significant.
Conclusions: These results demonstrate that the acute, prophylactic systems can be used to identify compounds
with therapeutic potential, but may not predict a compound’s efficacy in chronic smoke exposure models.
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Chronic obstructive pulmonary disease (COPD) is a
leading cause of hospitalizations and death worldwide.
The most common cause of COPD is chronic smoking,
which elicits a repetitive inflammatory insult that is
thought to lead to airway remodeling and, consequently,
to the accelerated lung function decline that charac-
terizes the disease. Unlike other chronic inflammatory
airway diseases like asthma, there are currently no ther-
apeutic approaches (e.g., glucocorticoids) that can
attenuate the inflammation associated with COPD. This
suggests that there is something different about the
molecular mechanisms regulating the cigarette smoke-
induced inflammation associated with the disease, which
at present is not understood.
Preclinical in vivo models of cigarette smoke-induced
lung inflammation are commonly used to investigate
prospective disease mechanisms and evaluate the effi-
cacy of candidate compounds. Exposure of laboratory
animals to cigarette smoke can recapitulate many of the
central features of COPD, including a slowly resolving
and steroid-resistant inflammation, mucus production,
airway remodeling, emphysema and changes in lung
function [1-4]. Although these models use the primary
etiological factor to mimic several COPD-like changes,
it is difficult to determine how reliable these models are
for predicting the therapeutic efficacy of candidate com-
pounds. For instance, while steroids lack efficacy in both
the preclinical models and the clinic, approaches aimed
at neutralizing TNF-alpha work in the preclinical mod-
els, but do not work in the clinic. In the latter example,
a possible reason for the lack of translation is that in
the preclinical models genetically modified mice defi-
cient for the TNF-alpha receptors were used and thus,
in these animals the initiation of the inflammatory
response to cigarette smoke exposure (CSE) was attenu-
ated [5,6]. This was clearly a different situation to that
in the clinic where an anti-TNF-alpha antibody lacked
the ability to affect the progression of ongoing
disease [7].
In most studies, compounds which have efficacy in
acute systems also have efficacy in chronic models, too.
The caveat to this is that most preclinical investigations
have focused on characterizing the effects of candidate
mechanisms under prophylactic conditions (using either
GM mice or compounds) whether in acute or chronic
CSE models [2,8-13]. Unfortunately, this approach does
not closely resemble the clinical scenario where patients
are treated after chronic lung inflammation has already
developed. Additionally, the inflammatory response to
CSE appears to be bi-phasic, with an initial neutrophilic
infiltrate peaking within one week of exposures. This is
subsequently followed by a more pronounced
inflammation after one month of CSEs with progressive
increases in neutrophils, macrophages and lymphocytes
migrating to the airways [1,14]. The different kinetics
and types of infiltrate suggests that there are potentially
different mechanisms driving the two phases of this
response; thus, a compound’se f f i c a c ym a yb ed i f f e r e n t
in an acute, prophylactic (< one week) versus chronic,
therapeutic (> one month) model. This concept is sup-
ported by the observation that TLR4 knockout mice are
partially protected from developing lung inflammation
after acute CSE, but were not protected after chronic
CSEs [15].
As such, the aim of this study was to compare the
prophylactic and therapeutic effects of three broad spec-
trum anti-inflammatory compounds in acute and
chronic CSE models, respectively. We focused on three
compounds with distinct mechanisms of action - a glu-
cocorticoid (budesonide), a phosphodiesterase (PDE) 4
inhibitor (roflumilast) and a statin (fluvastatin). As one
of the primary functions of preclinical disease models is
to assess the potential efficacy of candidate compounds,
ideally one would examine the same endpoints in the
models as in the clinic. Typically, early proof-of-concept
studies for COPD anti-inflammatory strategies in man
assess inflammatory cell numbers in biofluids such as
bronchoalveolar lavage fluid (BALF) or induced sputum,
while longer term clinical studies examine changes in
lung functioning. As the latter changes are difficult to
model in small animals, we focused on assessing the
effects of these anti-inflammatory compounds on CSE-
induced changes in BALF inflammatory cell numbers.
Methods
Materials
C57BL/6 mice were obtained from Charles River UK.
Budesonide [16,17-Butylidenebis(oxy)-11,21-dihydroxy-
pregna-1,4-diene-3,20-dione] was purchased from
Sigma. Roflumilast [3-(cyclopropylmethoxy)-N-(3, 5-
dichloropyridin-4-yl)-4-(difluoromethoxy) benzami] and
fluvastatin [(3R, 5S, 6E)-7-[3-(4-fluorophenyl)-1-(pro-
pan-2-yl)-1H-indol-2-yl]-3, 5-dihydroxyhept-6-enoic
acid] were made in-house (Novartis Institutes for Bio-
Medical Research, Basel, Switzerland). University of
Kentucky Research Cigarettes (brand 1R3F) were
obtained from the University of Kentucky (Louisville,
KY, USA).
Animal Maintenance Conditions
Female, C57BL/6 mice (16-20 g) were housed in rooms
maintained at constant temperature (21 ± 2°C) and
humidity (55 ± 15%) with a 12 h light cycle and 15 - 20
air changes per h. Ten animals were housed per cage
containing two nest packs filled with grade 6 sawdust
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Dri, Lillico, UK), maxi fun tunnels and Aspen chew
blocks (Lillico, UK) to provide environmental enrich-
ment. Animals were allowed food, RM1 Pellets, (SDS
UK Ltd.) and water ad libitum.
Statement on Animal Welfare
Studies described herein were performed under a Pro-
ject License issued by the United Kingdom Home Office
and protocols were approved by the Local Ethical
Review Process at Novartis Institutes for BioMedical
Research, Horsham.
Cigarette smoke exposure methodology
Cigarette smoke and sham exposures were performed as
previously described [10]. Mice were exposed to 4 cigar-
ettes per exposure period, which we had previously
shown to elicit a submaximal inflammatory response [10].
Sham, age- and sex-matched control animals were
exposed to room-air pumped into the exposure chambers
for the same duration of time (approximately 45 minutes
per exposure period).
Comparing inflammatory cell infiltrate after acute or
chronic CSE
Mice were exposed as described above once a day for
either 3 days or 5 days per week for 12 weeks. Ani-
mals were sacrificed with an overdose of terminal
anesthetic (sodium pentobarbitone 200 mg i.p.) fol-
lowed by exsanguination 24 hours after the last expo-
sure. There were sham, time-matched controls for
each time point.
Assessing compound efficacy in models of acute CSE-
induced inflammation
For the acute CSE model, the CSE regimen was per-
formed as described above once a day and for 3 conse-
cutive days. For studies with budesonide, the mice were
dosed with either budesonide (1 mg kg
-1) or vehicle (sal-
ine with 2% NMP) 1 hour before each air or smoke
exposure by intranasal (i.n.) administration under short-
acting anaesthetic as described previously [10]. For stu-
dies with roflumilast and fluvastatin, the mice were
dosed with either roflumilast (3 mg kg
-1) or fluvastatin
(2 mg kg
-1) or vehicle (0.5% CMC) per os (p.o.) 1 hour
before and (for fluvastatin-treated and vehicle control
mice) 5 hours after each air or smoke exposure. The
doses and dosing schedule for each compound were
based on those that we and others have previously
shown to be effective in other preclinical mouse models
[9,13,16,17]. Twenty-four hours after the last exposure,
animals were sacrificed with an overdose of terminal
anesthetic (sodium pentobarbitone 200 mg i.p.) followed
by exsanguination.
Assessing compound efficacy in models of chronic CSE-
induced inflammation
For the chronic CSE model, the CSE regimen was per-
formed as described above once a day, 5 days a week,
for 14 weeks. During weeks thirteen and fourteen, mice
were dosed with compounds or vehicles (as described
above) concurrent with CSE. As before, animals were
sacrificed with an overdose of terminal anaesthetic
(sodium pentobarbitone 20 mg i.p.) followed by exsan-
guination 24 hours after the last exposure.
Preparation of bronchoalveolar lavage fluid (BALF)
After animals were sacrificed, BALF was collected, pro-
cessed, and BALF inflammatory cell numbers deter-
mined as described previously [10].
Statistical Analysis
All data are presented as Mean ± Standard Error of Mean
(SEM). For time course studies, a Student’s t-test was
used comparing all smoke-exposed animals to their cor-
responding time-matched sham-exposed controls. For
the compound studies, a one-way ANOVA with Dunnett
correction for multiple comparisons was used. A P value
of less than 0.05 was considered significant. Power calcu-
lations were based on t-tests, assuming unequal variances
(Satterthwaite approximation), and were based on group
means and standard deviations derived from historical
data. All sample sizes were based on 80% power with a
two-sided alpha = 0.05. Calculations were performed
using the software package NQUERY ADVISOR.
Results
Time-dependent changes in BALF inflammatory cell
numbers over 3 months of CSE
In a previous study we confirmed the bi-phasic nature of
the inflammatory response to CSE over a 26 week period
(data not shown). The data in figure 1, was from a sepa-
rate study comparing the inflammatory phenotypes that
are observed after an acute (3 days) or chronic (12
weeks) exposure period. Both acute and chronic CSE
increased the numbers of BALF neutrophils recovered
(Figure 1A), although it’s clear chronic exposure led to a
greater increase relative to each groups’ respective sham
controls. The numbers of neutrophils increased more
than 5-fold over the 2.2 ± 0.4 × 10
3 cells mL
-1 recovered
in the sham-exposed controls (p > 0.01) after 3 days of
CSE; however, there was more than a 200-fold increase
over the 1.7 ± 0.9 × 10
2 cells mL
-1 recovered in the
sham-exposed mice after 12 weeks of CSE (p > 0.001).
Increases in BALF macrophages (Figures 1B), and lym-
phocytes (Figures 1C) were only observed after chronic
CSE. After 3 days of CSE, there were no significant
increases over the numbers of macrophages (9.7 ± 1.0 ×
10
4 cells mL
-1) or lymphocytes (1.6 ± 0.8 × 10
3 cells mL
-1)
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weeks of CSE, however, the numbers of macrophages
increased more than 2-fold over the 4.2 ± 0.9 × 10
4 cells
mL
-1 recovered in the sham-exposed mice (p > 0.01).
Similarly, BALF lymphocyte numbers increased more than
10-fold over the 3.0 ± 1.1 × 10
3 cells mL
-1 recovered in
the sham-exposed mice (p > 0.01).
Effect of prophylactically administered anti-inflammatory
compounds on CSE-induced acute inflammation
After 3 days of CSE, there was an increase in BALF neu-
trophil numbers in vehicle-treated mice compared to
sham-exposed, vehicle-treated controls (p < 0.01) (figure
2A-C). Budesonide, administered i.n., had no effect on
neutrophil numbers (Figure 2A). Conversely, roflumilast
(Figure 2B) and fluvastatin (Figure 2C) administered p.o.
significantly reduced the numbers of BALF neutrophils
by 87 ± 5% and 71 ± 9%, respectively (p < 0.01).
Effect of therapeutically administered anti-inflammatory
compounds on CSE-induced chronic inflammation
Chronic CSE increased the numbers of BALF neutro-
phils, macrophages and lymphocytes in the all
vehicle-treated groups compared to sham-exposed, vehi-
cle-treated controls. Budesonide (1 mg kg
-1, i.n., q.d.)
had no effect on BALF neutrophil or macrophage
numbers (Figure 3A and 3B). Budesonide did, however,
reduce the number of lymphocytes recovered by 91 ±
4% (p < 0.01) (Figure 3C). Roflumilast trended towards
reducing the increase in BALF neutrophils by 40 ± 10%
( F i g u r e4 A ) ,m a c r o p h a g e sb y4 7±1 3 %( F i g u r e4 B )a n d
lymphocytes by 56 ± 10% (Figure 4C); however these
effects on BALF leukocyte numbers were not statistically
significant. Fluvastatin reduced the number of neutro-
phils by 74 ± 5% (Figure 5A) and macrophages by 64 ±
7% (Figure 5B) in the BALF (p < 0.05), but the reduc-
tion of BALF lymphocytes was not statistically signifi-
cant (Figure 5C).
Discussion
These data confirm that there are different inflammatory
phenotypes after either an acute or chronic CSE. The
most obvious difference being the greater numbers and
spectrum of inflammatory cell infiltrate present in the
airways after a chronic exposure compared to the predo-
minantly low-grade neutrophilic inflammation after an
acute exposure. We also demonstrated that the acute
(prophylactic) CSE models can be used to identify com-
pounds with potential anti-inflammatory efficacy, but
could not be used to predict the therapeutic efficacy
of the same compounds on chronic CSE-induced
inflammation. This is the first time the prophylactic and
therapeutic effects of these 3 broad spectrum anti-
inflammatory compounds have been assessed in these
models. Again, we focused our assessment of efficacy
around the numbers of inflammatory cells recovered in
the BALF as this is a direct preclinical correlate to end-
points used in early proof-of-concept studies in man.
Additionally, infiltrating inflammatory cells (particularly
macrophages and lymphocytes) have been directly linked
to the subsequent development of COPD-like lung
pathologies in these modeling systems [18,19]. We did
not assess levels of cytokines or chemokines in the
BALF or lung tissue for several reasons. First, changes
in the levels of these mediators are not acceptable bio-
markers at the present time for studies conducted in
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Figure 1 Comparison of inflammatory cell profile after acute
versus chronic CSE. Acute (3 days) and chronic (12 weeks) CSE
increased BALF neutrophils (A); however, only chronic CSE increased
the numbers of BALF macrophages (B), and lymphocytes (C) in
C57BL/6 mice. Data is presented as the fold-increase in the numbers
of cells recovered in the BALF compared to the average of each
respective sham-exposed control group. Data from smoke-exposed
mice are represented by black bars and data from sham controls
represented by gray bars. Data plotted as the mean ± sem with an
n = 8-10 for each group. Significance (* = p < 0.05, ** = p < 0.01,
*** = p < 0.001) was determined versus sham control group.
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Page 4 of 10COPD patients because they do not consistently track
with disease progression. Second, we and others [20,21]
have shown that the effects anti-inflammatory molecules
(e.g. steroids) have on chemokine levels do not necessa-
rily align with their ability to block cell infiltrates.
Finally, investigating the molecular mechanisms respon-
sible for the effects of these 3 compounds in the models
was beyond the scope of these studies and (for the rea-
sons just described) would require more than an assess-
ment of cytokine or chemokine production. These data
will, however, be important to collect in future studies
elucidating the specific mechanisms of these compounds
in these models.
The response to CSE in rodents has both an acute
phase consisting of neutrophil infiltrate peaking after
one week of exposures and a chronic phase consisting
of neutrophils, macrophag e sa n dl y m p h o c y t e st h a t
begins after one month of exposures as previously
reported by us and others [1,14]. Between weeks 1 and
4 the inflammation goes through a transition period,
where neutrophil numbers decline, while macrophages
and lymphocytes begin to increase, but not in a comple-
tely progressive fashion. After 1 month the inflammatory
response is progressive, more pronounced, and even-
tually leads to airway remodeling and emphysema. We
tested 3 mechanistically distinct anti-inflammatory com-
pounds in both the 3-day and 14-week CSE models to
determine whether these subtle differences in the
inflammatory phenotype during each phase of the
response affected compound efficacy.
In the acute models, CSE consistently induced an
increase in the number of neutrophils recovered in the
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Figure 2 The effect of budesonide, roflumilast and fluvastatin on acute CSE-induced neutrophil infiltrate. (A) Budesonide (i.n., q.d.) had
no effect on CSE-induced neutrophil infiltrate in mice after 3 days of exposure. (B) Roflumilast (p.o., q.d.) and (C) Fluvastatin (p.o., b.i.d.) did
attenuate neutrophil infiltration. Data from CSE mice are represented by black bars, data from sham controls represented by white bars, data
from the CSE with compound treatment in gray, diagonal-striped bars. Data plotted as the mean ± sem with an n = 7-10 for each group.
Significance (* = p < 0.05, ** = p < 0.01, *** = p < 0.001) was determined versus smoke vehicle control group.
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Page 5 of 10BALF and as such this remained the primary endpoint
in the acute model. We and others have previously
shown that glucocorticoids cannot affect the acute
inflammatory changes induced by CSE at doses which
can attenuate allergen-induced inflammation [2,9,13,22].
We confirmed our previous findings (conducted using
BALB/C mice) here, using C57BL/6 mice as again bude-
sonide had no effect on acute CSE-induced neutrophilia
in this strain. Similarly, budesonide had no effect on
chronic CSE-induced macrophage or neutrophil infiltra-
tion in the lung. There was, however, a profound effect
on lymphocytic infiltrate that may be due to budeso-
nide’s effect on the thymus [23,24]; however, the
mechanism for this effect on lymphocytes still requires
further investigation. These findings reflect the inability
of glucocorticoids to attenuate the inflammation
observed in COPD patients. Additionally, the data
suggest that the CSE models can be used for investigat-
ing mechanisms related to steroid-resistant inflamma-
tion and for identifying approaches that may be able to
restore steroid efficacy in COPD [2].
Statins, on the other hand, have been reported to slow
the rate of lung function decline and reduce mortality in
COPD patients [25,26]; however, no one as yet has
looked at whether statins affect the inflammation asso-
ciated with the disease. Prophylactic administration of a
statin (i.e., simvastatin) has previously been demon-
strated to inhibit inflammation, emphysema and remo-
deling of the lung vasculature after chronic CSE in
Sprague-Dawley rats [13]. It is unclear how statins act
as anti-inflammatory agents, although their ability to
block adhesion molecules and preventing the prenyla-
tion of proteins involved in inflammatory signaling (e.g.
GTP-binding proteins) are well documented [27-29].
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Page 6 of 10In our acute (prophylactic) system, fluvastatin attenu-
ated acute neutrophilia induced by CSE. When we
tested fluvastatin in the more chronic (therapeutic)
model, it reduced the numbers of neutrophil and
macrophage recovered in the BALF, while there only a
modest reduction in lymphocyte infiltration, but the lat-
ter was not significant. These data are encouraging and
imply that statins may prove to be effective anti-inflam-
matory treatments for COPD.
We also assessed the effect of a PDE4 inhibitor, roflu-
milast, in our models as it has previously been shown to
reduce both acute and chronic CSE-induced inflamma-
tion in rodents when administered prophylactically at
similar doses [11,12,16]. Here, we show that while roflu-
milast can reduce acute CSE-induced inflammation
when given prophylactically, it failed to significantly
reduce an established chronic inflammation when admi-
nistered therapeutically. We propose that our results dif-
fer from those reported by Martorana and colleagues
[11] due to the different dosing schedules (prophylactic
versus therapeutic). Their results did, however, suggest
that higher doses were needed to inhibit the chronic
response. Our findings are in accordance with those
reported by Le Quement and colleagues [16] who found
that roflumilast reduced BALF neutrophils after 4 days
of CSE, but could not attenuate the numbers of BALF
macrophages after 11 days of CSE. The authors attribu-
ted these differences to PDE4 inhibitors’ inability to
inhibit macrophage activation and recruitment [16]. Our
data from the chronic CSE system demonstrate that
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Page 7 of 10roflumilast does not effectively reduce inflammatory cell
recruitment in general. These data, along with that
reported by Le Quement and colleagues [16], do suggest
that there are different mechanisms driving the acute
and chronic phases of the inflammatory response. Roflu-
milast has demonstrated very limited efficacy in the
clinic as well, which has largely been attributed to dose-
limitation associated with roflumilast’s side-effect profile.
It has been reported that roflumilast can reduce the
number of inflammatory cells recovered from COPD
patients by approximately 30-50% [30]. This level of
inhibition is consistent with what we observed in the
chronic CSE experiment; however, these in vivo models
are typically powered to identify a ≥ 50% inhibitory
effect. As such, these observations suggest that the
chronic model is a more rigorous assessment of a com-
pound’s anti-inflammatory efficacy that may be more
reflective of the clinical situation.
Conclusions
The data reported here demonstrate that overall, the
prophylactic effects of compounds in the acute CSE
models can identify compounds with anti-inflammatory
efficacy; however, effects in acute, prophylactic systems
did not reliably predict those observed in chronic mod-
els where compounds were administered therapeutically.
This suggests that mechanisms that are involved in the
initiation of CSE-induced inflammation may not be the
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Figure 5 The effect of fluvastatin on chronic CSE-induced inflammatory cell infiltrate. Fluvastatin (p.o., b.i.d.) reduced CSE-induced
neutrophil (A) and macrophage (B) infiltrate, but did not reduce the number of lymphocytes (C). Data from CSE mice are represented by black
bars, data from sham controls represented by white bars, data from the CSE with compound treatment in gray, diagonal-striped bars. Data
plotted as the mean ± sem with an n = 8-10 for each group. Significance (* = p < 0.05, ** = p < 0.01, *** = p < 0.001) was determined versus
smoke vehicle control group.
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Page 8 of 10same as those involved in the progression of the chronic
response. Thus, we conclude that the acute CSE model
is a robust, primary modelings y s t e mt h a tc a nb eu s e d
to assess the potential efficacy of candidate compounds,
particularly those with broad spectrum anti-inflammatory
effects or that target neutrophilic inflammation. How-
ever, testing candidate compounds in a chronic system
m o r ea k i nt ot h ec l i n i c a ls i t u a t i o nw h e r eap r o g r e s s i v e
chronic inflammation (with a broader spectrum of
inflammatory cell infiltrate) is already established in the
lungs would always be prudent to get a more complete
understanding of a compound’s range of effects.
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